Ultragenyx Pharmaceutical Inc. Stock
Ultragenyx Pharmaceutical Inc. shows a slight decrease today, losing -€0.190 (-0.820%) compared to yesterday.
The stock is an absolute favorite of our community with 26 Buy predictions and no Sell predictions.
Based on the current price of 22.98 € the target price of 50 € shows a potential of 117.58% for Ultragenyx Pharmaceutical Inc. which would more than double the current price.
Pros and Cons of Ultragenyx Pharmaceutical Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
S********** s********
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ultragenyx Pharmaceutical Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | -0.820% | 2.224% | -22.181% | -1.795% | 36.786% | -30.364% | -70.538% |
| Ligand Pharmaceuticals | 1.560% | -4.580% | -9.420% | 96.850% | 50.602% | 296.825% | 166.923% |
| United Therapeutics | -0.720% | -0.800% | -6.885% | 72.317% | 4.447% | 105.384% | 155.029% |
| Ionis Pharmaceuticals Inc. | -0.790% | 0.524% | -5.919% | 36.364% | -29.370% | 32.414% | 47.420% |
Comments
Ultragenyx Pharmaceutical (RARE) had its "buy" rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (RARE) had its price target lowered by Wells Fargo & Company from $47.00 to $45.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (RARE) had its price target lowered by Guggenheim from $43.00 to $35.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
News
Ultragenyx Pharmaceutical Q2 Earnings Call Highlights
Key Points
- Interested in Ultragenyx Pharmaceutical Inc.? Here are five stocks we like better.
- Ultragenyx reported record Q2 revenue of $214 million, led by Crysvita’s $156 million contribution
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
On May 14, 2026, Krensavage Asset Management disclosed it bought 241,245 shares of Ultragenyx Pharmaceutical (NASDAQ:RARE), an estimated $5.43 million trade based on quarterly average pricing.
